tailieunhanh - Báo cáo y học: "Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. | Available online http content 6 6 R535 Research article Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations a two-year prospective study Carole Ferraro-Peyret1 Fabienne Coury1 Jacques G Tebib2 Jacques Bienvenu1 and Nicole Fabien1 Open Access 1UF Autoimmunité Laboratoire d lmmunologie Centre Hospitalier Lyon-Sud Pierre Bénite France 2Service de Rhumatologie Centre Hospitalier Lyon-Sud Pierre Bénite France Corresponding author Nicole Fabien Received 22 Apr 2004 Revisions requested 2 Jun 2004 Revisions received 30 Jun 2004 Accepted 29 Jul 2004 Published 23 Sep 2004 Arthritis Res Ther 2004 6 R535-R543 DOI ar1440 2004 Ferraro-Peyret et al. licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is cited. Abstract Treatment of rheumatoid arthritis RA with infliximab Remicade has been associated with the induction of antinuclear autoantibodies ANA and anti-double-stranded DNA anti-dsDNA autoantibodies. In the present study we investigated the humoral immune response induced by infliximab against organ-specific or non-organ-specific antigens not only in RA patients but also in patients with ankylosing spondylitis AS during a two-year followup. The association between the presence of autoantibodies and clinical manifestations was then examined. The occurrence of the various autoantibodies was analyzed in 24 RA and 15 AS patients all treated with infliximab and in 30 RA patients receiving methotrexate but not infliximab using the appropriate methods of detection. Infliximab led to a significant induction of ANA and anti-dsDNA autoantibodies in and 57 of RA patients and in 85

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.